This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
San Diego-based Avalon Ventures , a venture capital firm focused on early stage high tech, digital media, and life sciences firms, said today that it has closed on $200M in capital commitments for its latest fund. Avalon said that the fund, Avalon Ventures IX, LP, is the ninth and largest fund for the company.
La Jolla-based venture capital investor Avalon Ventures has just received a $103M commitment to a new, $300M fund, according to a regulatory filing by the firm. The filing indicates that, so far, the fund has 26 investors in the first sale. READ MORE>>.
San Diego-based Avelas Biosciences has raised $7.65M in a Series A funding round, which it says will go towards clinical studies for its technology for real-time tumor visualization. The funding came from Avalon Ventures. Avelas is developing technology for visualizing cancerous lymph nodes in breast cancer patients.
San Diego-based Avelas Biosciences announced today that it has raised $6.85M in a Series B funding round, for the company''s technology for illuminating cancer cells. The company said the funding came from Avalon Ventures, and also included Torrey Pines Investment, WuXi AppTec, and an additional, un-named investor.
San Diego-based Chumby , which had developed Internet-connected, alarm-clock like devices and similar technology, has shut down, according to a report Friday. The firm had raised on the order of $25M in funding for its efforts. The firm had raised on the order of $25M in funding for its efforts. READ MORE>>.
Amount of the funding was not disclosed by the firm. According to E-Band, the round was led by Hercules Technology Growth Capital, and also included Avalon Ventures. E-Band said the funding will go towards accelerating its business operations expansion.
in a Series B funding. The second tranche of the company''s Series B came from investors Avalon Ventures, Torrey Pines Investment and WuXi PharmaTech Investments. The technology behind the Avelas product is based on research conducted at UC San Diego. READ MORE>>.
The largest deal was Sapphire Energy's $139M funding, followed by Fisker Automotive , which raised $129.72M, and Sientra , which raised $65.0M The largest sector of investment was Industrial/Energy, which includes clean technology, with $320.58M invested across Southern California. in 48 deals; Orange County had $249.3M in 13 deals.
in funding, according to a regulatory filing by the firm Monday. According to the filing, the funding came in the form of debt and warrants, most likely a convertible debt round. Source of the new funding was not disclosed. Chumby recently licensed the firm's technology to automotive software firm QNX Software Systems.
The $30M funding deal for Seattle's Cheezburger , the web publisher best known for its LOLcats-themed I Can Has Cheezburger? and FAIL Blog web sites, apparently was spawned out of an introduction at last year's Twiistup technology conference, according to investor the Foundry Group. READ MORE>>.
Proximal Data was venture backed by Divergent Ventures and Avalon Ventures, and had only announced around $5M in funding. Proximal Dat was led by Rory Bolt, a storage veteran who previously founded Avamar Technologies, which was acquired by EMC. Financial terms of the buy were not announced.
San Diego-based Proximal Data , which develops serve-side caching software for accelerating I/O access to virtualized machines, said this morning that it has raised $2M in a Series B round of funding. The funding came from Divergent Ventures, along with existing investors Avalon Ventures. The firm is led by Rory Bolt.
in venture funding. Orange County--boosted in a large part by a funding for Fisker Automotive--racked up $242.45M in funding. The biggest Los Angeles deal was a funding for SolarReserve , for $27.0M. The report found that the amounts invested represented the third highest annual investment total in the past ten years.
San Diego-based Synthorx , a developer of protein therapeutics technology, said it has raised $10M in a Series B financing this morning. The funding was led by RA Capital Management, and also included Avalon Ventures and Correlation Ventures. RA Capital Management's Andrew Levin joins the company's board with the funding.
Southern California's venture totals were significantly boosted by clean technology, and more specifically, financing for electric car manufacturers. Los Angeles saw $407.2M in 45 deals, Orange County saw $279.5M in 21 deals, and San Diego saw $170.6M invested in 24 deals. Both LA and OC were both up in terms of deals and dollars.
in a Series D funding. The firm said the round was led by Cardinal partners, and also included Venrock and prior investor Avalon Ventures. Awarepoint said the funding will go towards expansion of its product in both domestic and international markets. READ MORE>>
The funding was led by Avalon Ventures and TPG Biotech, and also included Correlation Ventures and Osage University Partners. Enlibrium said the technology has been exclusively licensed from UCLA. San Diego-based Enlibrium announced Thursday that it has raised $15M in a Series A financing, to go towards cancer therapeutics.
San Diego-based AristaMD , which is developing software tools to help coordinate referrals by physicians to specialists, has raised $11M in a Series A funding round. The funding was led by Avalon Ventures, and also included Correlation Ventures. READ MORE>>.
The startup--led by technology startup vet Derrick Oien--said the funding was led by Sinclair Digital Ventures, a division of Sinclair Broadcast Group. Also participating in the funding was Avalon Ventures, New Enterprise Associates, and angels, including Kevin Plank (Under Armour) and Paul Palmieri (Millennial Media).
[ Note: The headline has been corrected to better describe the company’s type of funding. Fortis Therapeutics, a new San Diego biotech, has raised $18 million in initial funding to develop drugs for hard-to-treat prostate and bone marrow cancers. 9/27/16, 2:09 p.m. Bregua Corp., We’re not inventing anything on the ADC,” he said.
How is your company funded? The round was led by Avalon Ventures, and we also had participation from Acciom Venture Lab, a socially responsible venture fund out of Washington, D.C. Michael Aleles: Most of our customers and recipients are not very technology savvy. However, technology is what allows us to do what we do.
Most sectors saw drops in investment during the year, with the exception of few--including a couple of sectors where Southern California has a significant presence, in Clean Technology and Media & Entertainment. in funding, driven in a large part by a $32M round for Solarflare Communications. billion in 277 deals.
San Diego’s Avelas Biosciences , founded in 2009 to advance a fluorescing biologic agent intended to help surgeons differentiate cancerous tissue from healthy tissue, has completed a $20 million Series C round of venture funding. and San Diego’s Avalon Ventures. and San Diego’s Avalon Ventures.
Synthorx, the San Diego synthetic biology startup that expanded the number of DNA base pairs with two synthetic nucleotides, said today it has raised $10 million in a Series B financing round led by RA Capital Management, the Boston life sciences hedge fund. Existing investors Avalon Ventures and Correlation Ventures joined in the round.
Alex Roudi, the San Diego investor backing the Plug and Play program here, has described the local effort as a bridge to Silicon Valley, by enabling the San Diego companies to make connections and raise funding in the Bay Area. The other partners are Edward Adato and Daniel Schwarzblat.). It’s really cool.”.
After demonstrating in 2016 how its synthetic biology technology could produce new biologic drugs , San Diego’s Synthorx today revealed that its lead drug candidate is an improved version of interleukin-2, an anti-cancer drug of intense commercial interest in the 1980s.
It was during this time, she recalled, when Bock met Kevin Kinsella of San Diego’s Avalon Ventures. In 1998, Nelsen recalled, “People thought we were crazy” to apply optics to genotyping when Affymetrix and its solid phase arrays represented the dominant technology at the time. They had a lot of fun.”.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content